Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Quest Clinical Research
With
Gilead Sciences
Age
45–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
HIV positive Males, age 45 or older
Any genotypic or phenotypic resistance except k65R, 69 insertion, integrase resistance, or resistance to rilpivarine or doravirine.
Receiving combination antiretroviral regimen of rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir \> 12 months and with viral load \<50 copies/ mL on at least one occasion within the six months prior to switch.
Suppressed viral load as defined by one plasma HIV RNA level \< 50 copies/mL within previous 6 months.
Capable of providing informed consent
You may not be if
Any current or prior integrase inhibitor resistance
Nucleoside reverse transcriptase (NRTI) mutation 69 insertion or k65R mutation
Documented second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance (rilpivirine or doravirine)
Clareo Health | Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine
